Stay updated on Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial
Sign up to get notified when there's something new on the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page.
Latest updates to the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page
- Check4 days agoChange DetectedThe website has been updated to version 2.10.3, with the notable removal of FDA Safety Alerts and Recalls from the previous version 2.10.2.SummaryDifference0.2%
- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe website has been updated from version 2.10.0 to 2.10.2, indicating new features or improvements.SummaryDifference0.1%
- Check32 days agoNo Change Detected
- Check47 days agoChange DetectedThe study has expanded to include 136 locations and has been updated from revision v2.9.7 to v2.10.0.SummaryDifference0.3%
- Check54 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.1%
- Check67 days agoChange DetectedThe change in the web page value represents the addition of a DOI (Digital Object Identifier) for the erratum related to the publication in Lancet Oncol. 2021 Oct;22(10):e428.SummaryDifference0.1%
- Check68 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content.SummaryDifference0.1%
Stay in the know with updates to Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page.